New BRCA2 gene variants associated with moderate risk of breast cancer

Mayo Clinic researchers, in a study published in Nature Communications, have identified a group of BRCA2 gene variants associated with a moderate risk of breast cancer, a finding that could help healthcare teams better assess a person's cancer risk and personalize care. 

The researchers studied 70 BRCA2 gene variants, that they labeled as hypomorphic variants because they only partially disrupt BRCA2 function. They examined how these variants affect the way BRCA2 works and analyzed genetic testing data from a large number of people who had undergone hereditary cancer testing. 

Researchers within the study note that individuals who inherit these specific gene changes are estimated to have a 20% to 25% lifetime risk of developing breast cancer. By comparison, people with more common harmful BRCA2 variants may have a 50% to 70% lifetime risk. Because of this reduced risk, these variants are also labeled as reduced penetrance pathogenic variants. 

This shows that not all harmful BRCA2 variants carry the same level of breast cancer risk. Understanding these differences could help us better match cancer prevention and screening strategies to an individual's actual risk." 

Fergus Couch, Ph.D., breast cancer researcher, Mayo Clinic Comprehensive Cancer Center

The findings have potential implications for cancer screening and prevention. The researchers note that people who carry these variants may still qualify for and benefit from regular mammograms and breast MRI. However, a more precise understanding of risk could be important when patients and their healthcare teams consider risk-reducing surgery. 

"A small subset of breast cancers are likely caused by BRCA2 hypomorphs," says Dr. Couch. "Women and men who inherit these variants should benefit from risk management strategies tailored to the level of risk associated with the specific variant." 

The researchers also examined whether tumors associated with these variants may be sensitive to PARP inhibitors, a class of targeted cancer drugs that interfere with the ability of cancer cells to repair damaged DNA. 

Their findings suggest that some of the tumors associated with hypomorphic BRCA2 variants may respond to PARP inhibitors. Tumor testing may help determine whether this type of treatment is appropriate for an individual patient. 

The researchers are continuing to identify and characterize hypomorphic variants in the BRCA1 and BRCA2 genes associated with inherited breast cancer risk. 

"Once the hypomorphic variants are all identified, we will be able to better define risk management and therapeutic strategies for those who carry these variants," Dr. Couch says. 

The research was conducted in collaboration with investigators from Ambry Genetics.

Source:
Journal reference:

Huang, H., et al. (2026). Partially functional hypomorphic missense variants in BRCA2 are reduced penetrance pathogenic variants. Nature Communications. DOI: 10.1038/s41467-026-79433-5. https://www.nature.com/articles/s41467-026-79433-5

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Broad genomic sequencing extends survival in advanced lung cancer patients